Chardan Capital analyst Gbola Amusa maintained a Buy rating on Applied Genetic Technologies (NASDAQ: AGTC) today. The company’s shares closed yesterday at $4.15.
Amusa said:
“We understand the GT guidelines for hemophilia, retinal diseases, and rare diseases are the 1st of their kind from the regulator, while those on CMC, retroviruses, and long- term follow-up are refreshed from 2006-2008 versions. All 6 documents can be found here. Below, we highlight features of each set of guidelines we find most relevant to companies under our coverage and to the broader GT space.”
According to TipRanks.com, Amusa is a top 100 analyst with an average return of 29.9% and a 55.9% success rate. Amusa covers the Healthcare sector, focusing on stocks such as Spring Bank Pharmaceuticals Inc, Nightstar Therapeutics Limited, and Iovance Biotherapeutics Inc.
Currently, the analyst consensus on Applied Genetic Technologies is a Moderate Buy with an average price target of $8.
See today’s analyst top recommended stocks >>
The company has a one-year high of $5.75 and a one-year low of $3.25. Currently, Applied Genetic Technologies has an average volume of 102.2K.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Applied Genetic Technologies Corp. is a clinical-stage biotechnology company, which engages in the development of gene therapy products designed to transform the lives of patients with severe diseases in ophthalmology. Its product candidates are designed to treat X-linked retinoschisis, Achromatopsia, and X-linked retinitis pigmentosa.
